The American College of Rheumatology (ACR), which represents over 9500 rheumatologists and rheumatology health professionals, recently submitted a letter to HHS in response to the department’s request for information on Promoting Healthcare Choice and Competition Across the United States.
The American College of Rheumatology (ACR), which represents over 9500 rheumatologists and rheumatology health professionals, recently submitted a letter to HHS in response to the department’s request for information on Promoting Healthcare Choice and Competition Across the United States.
In the letter, the ACR applauded CMS’ recent decision to assign unique J-codes to each biosimilar of a reference product and encouraged HHS to continue to support biosimilar innovation. Allowing biosimilars to have their own unique J-code ensures better monitoring of their effectiveness while allowing for sufficient pharmacovigilance.
ACR urged Congressional leaders to reverse a recent decision to adjust providers’ reimbursement for Part B drug costs based on their performance under the Merit-Based Incentive Payment System (MIPS), despite these drugs’ costs being outside physician control. ACR claims that both reforms are essential to advancing the current administration’s goals of promoting healthcare choice and competition.
“This dangerous policy penalizes the doctors who administer Part B therapies and will ultimately reduce patient access to treatments for diseases like arthritis and cancer, particularly in rural and underserved areas of the United States. This is in direct conflict with the Administration’s goal of promoting patient choice,” said David Daikh, MD, PhD, president of ACR, in a statement.
ACR also called on HHS to address the problem of prior authorizations. The letter cites a 2016 American Medical Association (AMA) survey that found that medical practices on average complete 37 prior authorization requirements per week, per physician. This process takes about 16 hours (or 2 full business days). ACR says that CMS (and other entities that are engaged in reform) should follow a group of principles outlined in the letter:
“The current prior authorization process leads to a waste of valuable resources that delays care and does not add value to the healthcare delivery system. We encourage HHS and all agencies involved in utilization management to follow a set of best practices that ensure utilization management programs are reasonably designed and implemented,” said Daikh.
Another area of concern for ACR is the need for increased transparency from pharmacy benefit managers (PBMs). The ACR suggested that CMS consider policies that provide more transparency about PBMs payment practices, including the true cost of drugs. ACR also encouraged HHS to require more consistency in the way PBMs structure their rebate programs, including uniform definitions for terms used in disclosures, such as specifying what constitutes a rebate, discount, fee, and amount received from a manufacturer.
Along with ACR, more than 100 healthcare organizations sent letters to congressional leaders urging them to reverse the CMS policy, cautioning that it will create a tremendous financial risk for specialists that administer Part B drugs and lead to significant access problems for patients that rely on these therapies.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
2 Commerce Drive
Cranbury, NJ 08512